InMed Q1 FY2025 revenue $1.3M (+40% YoY); net loss narrows to $1.68M

InMed Pharmaceuticals Inc.

2025-Q1 EPS reported -$2.71 revenue$1,264,638

BayMedica revenue $1.3M, up 40% YoY; BayMedica generated $0.3M net income (24% margin).
Net loss narrowed to $1.68M ($2.17/sh) from $2.54M ($15.24/sh) in Q1 FY2024.
Cash and equivalents $5.6M at Sep 30, 2024, down from $6.6M at June 30, 2024; expects cash to fund through Q1 calendar 2025.
Reverse stock split effective Nov 14, 2024 to regain Nasdaq minimum bid price compliance.
Preclinical data for Alzheimer's candidate INM-901 shows oral bioavailability and significant behavioral results; data expected Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.